A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of of VSA012 in Subjects with Paroxysmal Nocturnal Hemoglobinuria(PNH)
Not yet recruitingOBSERVATIONAL
Enrollment
16
Participants
Timeline
Start Date
April 30, 2025
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
All Listed Sponsors
lead
Visirna Therapeutics HK Limited
INDUSTRY
NCT06848296 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of of VSA012 in Subjects with Paroxysmal Nocturnal Hemoglobinuria(PNH) | Biotech Hunter | Biotech Hunter